BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE: payments to doctors

Payments that named BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.

The per-transaction average — $37,119 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. No payment naming this product was reported to an individual clinician. The Sunshine Act also covers payments to teaching hospitals as institutions — research funding, grants and device loans — and for this product that is all of it.